Terms: = Lung cancer AND MYH9, P35579, 4627, ENSG00000100345, DFNA17 AND Treatment
4 results:
1. TMEM120B strengthens breast cancer cell stemness and accelerates chemotherapy resistance via β1-integrin/FAK-TAZ-mTOR signaling axis by binding to myh9.
Hu R; Cao Y; Wang Y; Zhao T; Yang K; Fan M; Guan M; Hou Y; Ying J; Ma X; Deng N; Sun X; Zhang Y; Zhang X
Breast Cancer Res; 2024 Mar; 26(1):48. PubMed ID: 38504374
[TBL] [Abstract] [Full Text] [Related]
2. LAMC2 mitigates ER stress by enhancing ER-mitochondria interaction via binding to myh9 and MYH10.
Tong D; Zhou J; Zhou J; Wang X; Gao B; Rui X; Liu L; Chen Q; Huang C
Cancer Gene Ther; 2024 Jan; 31(1):43-57. PubMed ID: 37891404
[TBL] [Abstract] [Full Text] [Related]
3. SAMD9 Promotes Postoperative Recurrence of Esophageal Squamous Cell Carcinoma by Stimulating myh9-Mediated GSK3β/β-Catenin Signaling.
Li Q; Luo H; Dai FQ; Wang RT; Fan XQ; Luo YY; Deng MS; Wang Y; Long T; Guo W; Xu B; Xu CX; Jin H
Adv Sci (Weinh); 2023 Apr; 10(11):e2203573. PubMed ID: 36757050
[TBL] [Abstract] [Full Text] [Related]
4. Circular RNA PRMT5 knockdown enhances cisplatin sensitivity and immune response in non-small cell lung cancer by regulating miR-138-5p/myh9 axis.
Xu Y; Zhao R; Wang H; Jiang J; Wang Z; Wang J; Zhang W; Li M
J BUON; 2021; 26(5):1850-1861. PubMed ID: 34761592
[TBL] [Abstract] [Full Text] [Related]
